NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
NanoViricides, Inc. (NYSE American: NNVC) announced that its antiviral drug candidate NV-387 may address the growing global measles outbreak, citing recent case surges including more than 18,000 suspected infections in Bangladesh and rising cases in the United States. The company stated that NV-387 has demonstrated safety in Phase I clinical trials and efficacy in animal models, positioning it as a potential therapeutic complement to vaccination by reducing transmission and treating infected patients, particularly among vulnerable populations.
The announcement comes as measles cases are increasing globally, creating an urgent need for additional treatment options alongside vaccination programs. NV-387 represents a broad-spectrum antiviral approach that could fill a critical gap in managing outbreaks. The company noted plans to pursue orphan and rare pediatric disease designations with the FDA, which could accelerate development pathways for this potential treatment.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy, with NV-387 as its lead drug candidate. According to company information available at https://www.nanoviricides.com, NV-387 is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. The drug has also shown effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles.
The company's other advanced drug candidate is NV-HHV-1 for the treatment of all Herpesvirus infections including HSV-1 "cold sores," HSV-2 "genital ulcers," VZV Shingles and Chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs because of dependence on a number of external collaborators and consultants.
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is currently focused on advancing NV-387 into Phase II human clinical trials. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
The potential development of NV-387 as a measles treatment carries significant implications for global public health. Measles remains a leading cause of vaccine-preventable deaths worldwide, and therapeutic options could help manage outbreaks in areas with low vaccination coverage or among immunocompromised individuals who cannot receive vaccines. The company's approach of developing a broad-spectrum antiviral that addresses multiple viral threats represents a strategic response to pandemic preparedness needs.
BioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers various communication solutions. For more information, please visit https://www.BioMedWire.com.